In our series of 10 cases and controls, we found that control subjects fell into two groups—those with levels of BDNF mature-domain that are up to 20 times higher than AD cases (Fig. 5); however, an equal number of controls have mature-domain levels that are equivalent to AD patients. This evidence concerns the gene BDNF and Alzheimer disease.